Current Topics in Management of Non-Muscle Invasive Bladder Cancer
Non–muscle invasive bladder cancer (NMIBC) is the most commonly diagnosed form of bladder cancer. Better understanding of recommended treatment strategies during a bacillus Calmette Guérin (BCG) shortage, as well as familiarity with novel treatment options that may be on the horizon, will help educate clinicians on how to optimally treat NMIBC.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer
With an increasing number of treatment options for both non–muscle invasive bladder cancer (NMIBC) and advanced urothelial bladder cancer available, it is important for physicians to understand these various treatments and identify which option is likely to bring the greatest benefit to a specific patient.
Category
  • Bladder Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date September 24, 2020
New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation